Complex Small Molecules Are Changing Drug R&D

▤ Summary

This article explains how newer small-molecule modalities are increasing the complexity of drug discovery, development, and manufacturing. It highlights targeted protein degraders, covalent agents, and newer kinase inhibitors as examples that require different workflows than classical medicinal chemistry. It also argues that integrated discovery-to-manufacturing partners can shorten timelines by keeping decisions and quality systems continuous across handoffs. For software and services vendors, the piece signals demand for more connected platforms and operational capabilities across translational science, analytics, and manufacturing coordination.

▦ Linked Companies